

## Supplemental material

### Intra-arterial thrombolytics during endovascular thrombectomy for acute ischemic stroke in the MR CLEAN Registry

Sabine L. Collette, Reinoud P.H. Bokkers, Aryan Mazuri, Geert J. Lycklama à Nijeholt, Robert J. van Oostenbrugge, Natalie E. LeCouffe, Faysal Benali, Charles B.L.M. Majoie, Jan Cees de Groot, Gert Jan R. Luijckx, Maarten Uyttenboogaart; on behalf of the MR CLEAN Registry investigators.

**Figure S1.** Stratified analyses of the primary outcome

**Table S1.** Distribution of revascularization attempts and occlusion locations


**Table S2.** Baseline characteristics

**Table S3.** Procedural variables

**Table S4.** Baseline characteristics

**Table S5.** Procedural variables

**Supplemental Appendix.** MR CLEAN Registry Investigators – group authors

**Figure S1.** Stratified analyses of the primary outcome

EVT, endovascular thrombectomy; IA, intra-arterial.

CI, confidence interval.

The forest plot shows the odds ratios for favorable functional outcome (defined as modified Rankin Scale score  $\leq 2$ ) at 90 days across the prespecified subgroups. The dashed vertical line indicates no effect. The solid vertical line indicates the overall effect.

**Table S1.** Distribution of revascularization attempts and occlusion locations

<b>Location</b>	<b>Primary attempt (n=26)</b>	<b>Adjuvant attempt (n=60)</b>
<b>Proximal occlusion</b>	<b>18/26 (69.2)</b>	<b>47/60 (78.3)</b>
ICA	0 (0)	2/60 (3.3)
M1	7/26 (26.9)	18/60 (30.0)
M2	11/26 (42.3)	20/60 (33.3)
A1	0 (0)	1/60 (1.7)
A2	0 (0)	5/60 (8.3)
ACOM	0 (0)	1/60 (1.7)
<b>Distal occlusion</b>	<b>8/26 (30.8)</b>	<b>13/60 (21.7)</b>
M3	5/26 (19.2)	8/60 (13.3)
M4	2/26 (7.7)	1/60 (1.7)
A3	1/26 (3.8)	3/60 (5.0)
PCOM and P1	0 (0)	1/60 (1.7)

A1, anterior cerebral artery, first segment; A2, anterior cerebral artery, second segment; A3, anterior cerebral artery, third segment; ACOM, anterior communicating artery; ICA, internal carotid artery; M1, middle cerebral artery, first segment; M2, middle cerebral artery, second segment; M3, middle cerebral artery, third segment; M4, middle cerebral artery, fourth segment; P1, posterior cerebral artery, first segment; PCOM, posterior communicating artery.

**Table S2.** Baseline characteristics

<b>Characteristics</b>	<b>Primary attempt (n=26)</b>	<b>Adjuvant attempt (n=65)</b>	<b>P value</b>
Age, median (IQR), years	66 (53-77)	67 (56-74)	.99
Male, n (%)	15/26 (58)	32/65 (50)	.47
Medical history, n (%)			
Atrial fibrillation	7/26 (26.9)	6/65 (9.2)	.05
Diabetes mellitus	2/26 (7.7)	7/65 (10.8)	>.99
Hypercholesterolemia	5/26 (19.2)	17/65 (26.2)	.49
Hypertension	11/26 (42.3)	28/65 (43.1)	.95
Myocardial infarction	5/26 (19.2)	6/65 (9.2)	.28
Previous stroke	4/26 (15.4)	4/65 (6.2)	.22
Current smoker, n (%)	9/19 (47.4)	16/48 (33.3)	.28
Use of antiplatelet, n (%)	9/26 (34.6)	16/65 (24.6)	.33
Use of anticoagulation, n (%)	5/26 (19.2)	2/65 (3.1)	.02
Initial location occlusion on CTA, n (%)			
Left hemisphere	19/26 (73.1)	37/65 (56.9)	.15
Intracranial ICA	6/26 (23.1)	24/65 (36.9)	.45
M1	14/26 (53.8)	29/65 (44.6)	
M2	6/26 (23.1)	12/65 (18.5)	
A1	0/26 (0)	0/65 (0)	
A2	0/26 (0)	0/65 (0)	
Collateral status, n (%)			.64
Absent collaterals	1/25 (4.0)	5/62 (8.1)	
<50% of occluded area	10/25 (40.0)	21/62 (33.9)	
50-99% of occluded area	10/25 (40.0)	20/62 (32.3)	
100% of occluded area	4/25 (16.0)	16/62 (25.8)	
NIHSS score, median (IQR)	14 (7-17)	17 (11-20)	.08
Intravenous thrombolysis, n (%)	20/26 (76.9)	54/65 (83.1)	.56
Pre-intervention SBP, mean (SD), mm Hg	155 (26)	150 (27)	.44

A1, anterior cerebral artery, first segment; A2, anterior cerebral artery, second segment; CTA, computed tomography angiography; ICA, internal carotid artery; M1, middle cerebral artery, first segment; M2, middle cerebral artery, second segment; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure.

IQR, interquartile range; n, number; SD, standard deviation.

**Table S3.** Procedural variables

<b>Characteristics</b>	<b>Primary attempt (n=26)</b>	<b>Adjuvant attempt (n=65)</b>	<b>P value</b>
IA thrombolytics, n (%)			.62
Urokinase	17/26 (65.4)	46/65 (70.8)	
Alteplase	9/26 (34.6)	19/65 (29.2)	
Dose IA thrombolytics, median (IQR)			
Urokinase, IU	250,000 (125,000-375,000)	250,000 (200,000-250,000)	.94
Alteplase, mg	20 (10-20)	20 (16-20)	.75
General anesthesia, n (%)	9/25 (36.0)	23/61 (37.7)	.88
Time from stroke onset to groin puncture, median (IQR), minutes	193 (152-245)	205 (158-254)	.56
Time from groin puncture to recanalization or last contrast bolus, median (IQR), minutes	65 (45-75)	80 (65-118)	.01
IA, intra-arterial.			

IQR, interquartile range; n, number.

**Table S4.** Baseline characteristics

<b>Characteristics</b>	<b>Proximal occlusion (n=67)</b>	<b>Distal occlusion (n=21)</b>	<b>P value</b>
Age, median (IQR), years	69 (56-77)	65 (57-74)	.50
Male, n (%)	37/67 (56)	9/21 (43)	.32
Medical history, n (%)			
Atrial fibrillation	8/67 (11.9)	5/21 (23.8)	.29
Diabetes mellitus	6/67 (9.0)	3/21 (14.3)	.44
Hypercholesterolemia	19/67 (28.4)	3/21 (14.3)	.19
Hypertension	29/67 (43.3)	11/21 (52.4)	.47
Myocardial infarction	10/67 (14.9)	2/21 (9.5)	.72
Previous stroke	5/67 (7.5)	3/21 (14.3)	.39
Current smoker, n (%)	20/50 (40.0)	3/13 (23.1)	.34
Use of antiplatelet, n (%)	21/67 (31.3)	4/21 (19.0)	.28
Use of anticoagulation, n (%)	7/67 (10.4)	0/21 (0)	.19
Initial location occlusion on CTA, n (%)			
Left hemisphere	37/67 (55.2)	16/21 (76.2)	.09
Intracranial ICA	22/67 (32.8)	6/21 (28.6)	.57
M1	33/67 (49.3)	9/21 (42.9)	
M2	12/67 (17.9)	6/21 (28.6)	
A1	0/67 (0)	0/21 (0)	
A2	0/67 (0)	0/21 (0)	
Collateral status, n (%)			.57
Absent collaterals	4/65 (6.2)	2/19 (10.5)	
<50% of occluded area	22/65 (33.8)	6/19 (31.6)	
50-99% of occluded area	26/65 (40.0)	5/19 (26.3)	
100% of occluded area	13/65 (20.0)	6/19 (31.6)	
NIHSS score, median (IQR)	16 (10-19)	14 (6-19)	.32
Intravenous thrombolysis, n (%)	53/67 (79.1)	18/21 (85.7)	.75
Pre-intervention SBP, mean (SD), mm Hg	149 (25)	158 (29)	.17

A1, anterior cerebral artery, first segment; A2, anterior cerebral artery, second segment; CTA,

computed tomography angiography; ICA, internal carotid artery; M1, middle cerebral artery,

first segment; M2, middle cerebral artery, second segment; NIHSS, National Institutes of

Health Stroke Scale; SBP, systolic blood pressure.

IQR, interquartile range; n, number; SD, standard deviation.

**Table S5.** Procedural variables

<b>Characteristics</b>	<b>Proximal occlusion (n=67)</b>	<b>Distal occlusion (n=21)</b>	<b>P value</b>
IA thrombolytics, n (%)			.48
Urokinase	47/67 (70.1)	13/21 (61.9)	
Alteplase	20/67 (29.9)	8/21 (38.1)	
Dose IA thrombolytics, median (IQR)			
Urokinase, IU	250,000 (200,000-375,000)	200,000 (112,500-250,000)	.04
Alteplase, mg	20 (12-20)	20 (15-20)	.77
General anesthesia, n (%)	23/63 (36.5)	8/20 (40.0)	.78
Time from stroke onset to groin puncture, median (IQR), minutes	195 (145-242)	225 (193-283)	.04
Time from groin puncture to recanalization or last contrast bolus, median (IQR), minutes	70 (55-108)	78 (64-95)	.58

IA, intra-arterial.

IQR, interquartile range; n, number.

**Supplemental Appendix. MR CLEAN Registry Investigators – group authors****Executive committee**

Diederik W.J. Dippel<sup>1</sup>;Aad van der Lugt<sup>2</sup>;Charles B.L.M. Majoie<sup>3</sup>;Yvo B.W.E.M. Roos<sup>4</sup>;Robert J. van Oostenbrugge<sup>5</sup>;Wim H. van Zwam<sup>6</sup>;Jelis Boiten<sup>14</sup>;Jan Albert Vos<sup>8</sup>

**Study coordinators**

Ivo G.H. Jansen<sup>3</sup>;Maxim J.H.L. Mulder<sup>1,2</sup>;Robert Jan B. Goldhoorn<sup>5,6</sup>;Kars C.J. Compagne<sup>2</sup>;Manon Kappelhof<sup>3</sup>;Josje Brouwer<sup>4</sup>;Sanne J. den Hartog<sup>1,2,40</sup>;Wouter H. Hinsenvelde<sup>5,6</sup>

**Local principal investigators**

Diederik W.J. Dippel<sup>1</sup>;Bob Roozenbeek<sup>1</sup>;Aad van der Lugt<sup>2</sup>;Adriaan C.G.M. van Es<sup>2</sup>;Charles B.L.M. Majoie<sup>3</sup>;Yvo B.W.E.M. Roos<sup>4</sup>;Bart J. Emmer<sup>3</sup>;Jonathan M. Coutinho<sup>4</sup>;Wouter J. Schonewille<sup>7</sup>;Jan Albert Vos<sup>8</sup>;Marieke J.H. Wermer<sup>9</sup>;Marianne A.A. van Walderveen<sup>10</sup>;Julie Staals<sup>5</sup>;Robert J. van Oostenbrugge<sup>5</sup>;Wim H. van Zwam<sup>6</sup>;Jeannette Hofmeijer<sup>11</sup>;Jasper M. Martens<sup>12</sup>;Geert J. Lycklama à Nijeholt<sup>13</sup>;Jelis Boiten<sup>14</sup>;Sebastiaan F. de Bruijn<sup>15</sup>;Lukas C. van Dijk<sup>16</sup>;H. Bart van der Worp<sup>17</sup>;Rob H. Lo<sup>18</sup>;Ewoud J. van Dijk<sup>19</sup>;Hieronymus D. Boogaarts<sup>20</sup>;J. de Vries<sup>22</sup>;Paul L.M. de Kort<sup>21</sup>;Julia van Tuijl<sup>21</sup>;Jo P. Peluso<sup>26</sup>;Puck Fransen<sup>22</sup>;Jan S.P. van den Berg<sup>22</sup>;Boudewijn A.A.M. van Hasselt<sup>23</sup>;Leo A.M. Aerden<sup>24</sup>;René J. Dallinga<sup>25</sup>;Maarten Uyttenboogaart<sup>28</sup>;Omid Eschgi<sup>29</sup>;Reinoud P.H. Bokkers<sup>29</sup>;Tobien H.C.M.L. Schreuder<sup>30</sup>;Roel J.J. Heijboer<sup>31</sup>;Koos Keizer<sup>32</sup>;Lonneke S.F. Yo<sup>33</sup>;Heleen M. den Hertog<sup>22</sup>;Tomas Bulut<sup>35</sup>;Paul J.A.M. Brouwers<sup>34</sup>

**Imaging assessment committee**

Charles B.L.M. Majoie<sup>3</sup>(chair);Wim H. van Zwam<sup>6</sup>;Aad van der Lugt<sup>2</sup>;Geert J. Lycklama à Nijeholt<sup>13</sup>;Marianne A.A. van Walderveen<sup>10</sup>;Marieke E.S. Sprengers<sup>3</sup>;Sjoerd F.M.

Jenniskens<sup>27</sup>;René van den Berg<sup>3</sup>;Albert J. Yoo<sup>38</sup>;Ludo F.M. Beenen<sup>3</sup>;Alida A. Postma<sup>6</sup>;Stefan D. Roosendaal<sup>3</sup>;Bas F.W. van der Kallen<sup>13</sup>;Ido R. van den Wijngaard<sup>13</sup>;Adriaan C.G.M. van Es<sup>2</sup>;Bart J. Emmer<sup>3</sup>;Jasper M. Martens<sup>12</sup>; Lonneke S.F. Yo<sup>33</sup>;Jan Albert Vos<sup>8</sup>;Joost Bot<sup>36</sup>, Pieter-Jan van Doormaal<sup>2</sup>; Anton Meijer<sup>27</sup>;Elyas Ghariq<sup>13</sup>; Reinoud P.H. Bokkers<sup>29</sup>;Marc P. van Proosdij<sup>37</sup>;G. Menno Krietemeijer<sup>33</sup>;Jo P. Peluso<sup>26</sup>;Hieronymus D. Boogaarts<sup>20</sup>;Rob Lo<sup>18</sup>;Dick Gerrits<sup>35</sup>;Wouter Dinkelaar<sup>2</sup>Auke P.A. Appelman<sup>29</sup>;Bas Hammer<sup>16</sup>;Sjoert Pegge<sup>27</sup>;Anouk van der Hoorn<sup>29</sup>;Saman Vinke<sup>20</sup>.

### **Writing committee**

Diederik W.J. Dippel<sup>1</sup>(chair);Aad van der Lugt<sup>2</sup>;Charles B.L.M. Majoe<sup>3</sup>;Yvo B.W.E.M. Roos<sup>4</sup>;Robert J. van Oostenbrugge<sup>5</sup>;Wim H. van Zwam<sup>6</sup>;Geert J. Lycklama à Nijeholt<sup>13</sup>;Jelis Boiten<sup>14</sup>;Jan Albert Vos<sup>8</sup>;Wouter J. Schonewille<sup>7</sup>;Jeannette Hofmeijer<sup>11</sup>;Jasper M. Martens<sup>12</sup>;H. Bart van der Worp<sup>17</sup>;Rob H. Lo<sup>18</sup>

### **Adverse event committee**

Robert J. van Oostenbrugge<sup>5</sup>(chair);Jeannette Hofmeijer<sup>11</sup>;H. Zwenneke Flach<sup>23</sup>

### **Trial methodologist**

Hester F. Lingsma<sup>40</sup>

### **Research nurses / local trial coordinators**

Naziha el Ghannouti<sup>1</sup>;Martin Sterrenberg<sup>1</sup>;Wilma Pellikaan<sup>7</sup>;Rita Sprengers<sup>4</sup>;Marjan Elfrink<sup>11</sup>;Michelle Simons<sup>11</sup>;Marjolein Vossers<sup>12</sup>;Joke de Meris<sup>14</sup>;Tamara Vermeulen<sup>14</sup>;Annet Geerlings<sup>19</sup>;Gina van Vemde<sup>22</sup>;Tiny Simons<sup>30</sup>;Gert Messchendorp<sup>28</sup>;Nynke Nicolaij<sup>28</sup>;Hester Bongenaar<sup>32</sup>;Karin Bodde<sup>24</sup>;Sandra Kleijn<sup>34</sup>;Jasmijn Lodico<sup>34</sup>; Hanneke Droste<sup>34</sup>;Maureen

Wollaert<sup>5</sup>;Sabrina Verheesen<sup>5</sup>;D. Jeurissen<sup>5</sup>;Erna Bos<sup>9</sup>;Yvonne Drabbe<sup>15</sup>;Michelle Sandiman<sup>15</sup>;Nicoline Aaldering<sup>11</sup>;Berber Zweedijk<sup>17</sup>;Jocova Vervoort<sup>21</sup>;Eva Ponjee<sup>22</sup>;Sharon Romviel<sup>19</sup>;Karin Kanselaar<sup>19</sup>;Denn Barning<sup>10</sup>.

**PhD / Medical students:**

Esmee Venema<sup>40</sup>; Vicky Chalos<sup>1,40</sup>; Ralph R. Geuskens<sup>3</sup>; Tim van Straaten<sup>19</sup>;Saliha Ergezen<sup>1</sup>; Roger R.M. Harmsma<sup>1</sup>; Daan Muijres<sup>1</sup>; Anouk de Jong<sup>1</sup>;Olvert A. Berkhemer<sup>1,3,6</sup>;Anna M.M. Boers<sup>3,39</sup>; J. Huguet<sup>3</sup>;P.F.C. Groot<sup>3</sup>;Marieke A. Mens<sup>3</sup>;Katinka R. van Kranendonk<sup>3</sup>;Kilian M. Treurniet<sup>3</sup>;Manon L. Tolhuisen<sup>3,39</sup>;Heitor Alves<sup>3</sup>;Annick J. Weterings<sup>3</sup>,Eleonora L.F. Kirkels<sup>3</sup>,Eva J.H.F. Voogd<sup>11</sup>;Lieve M. Schupp<sup>3</sup>;Sabine L. Collette<sup>28,29</sup>;Adrien E.D. Groot<sup>4</sup>;Natalie E. LeCouffe<sup>4</sup>;Praneeta R. Konduri<sup>39</sup>;Haryadi Prasetya<sup>39</sup>;Nerea Arrarte-Terreros<sup>39</sup>;Lucas A. Ramos<sup>39</sup>.

**List of affiliations**

Department of Neurology<sup>1</sup>, Radiology<sup>2</sup>, Public Health<sup>40</sup>, Erasmus MC University Medical Center;

Department of Radiology and Nuclear Medicine<sup>3</sup>, Neurology<sup>4</sup>, Biomedical Engineering & Physics<sup>39</sup>, Amsterdam UMC, University of Amsterdam, Amsterdam;

Department of Neurology<sup>5</sup>, Radiology<sup>6</sup>, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht (CARIM);

Department of Neurology<sup>7</sup>, Radiology<sup>8</sup>, Sint Antonius Hospital, Nieuwegein;

Department of Neurology<sup>9</sup>, Radiology<sup>10</sup>, Leiden University Medical Center;

Department of Neurology<sup>11</sup>, Radiology<sup>12</sup>, Rijnstate Hospital, Arnhem;

Department of Radiology<sup>13</sup>, Neurology<sup>14</sup>, Haaglanden MC, the Hague;

Department of Neurology<sup>15</sup>, Radiology<sup>16</sup>, HAGA Hospital, the Hague;

Department of Neurology<sup>17</sup>, Radiology<sup>18</sup>, University Medical Center Utrecht;

Department of Neurology<sup>19</sup>, Neurosurgery<sup>20</sup>, Radiology<sup>27</sup>, Radboud University Medical Center, Nijmegen;

Department of Neurology<sup>21</sup>, Radiology<sup>26</sup>, Elisabeth-TweeSteden ziekenhuis, Tilburg;

Department of Neurology<sup>22</sup>, Radiology<sup>23</sup>, Isala Klinieken, Zwolle;

Department of Neurology<sup>24</sup>, Radiology<sup>25</sup>, Reinier de Graaf Gasthuis, Delft;

Department of Neurology<sup>28</sup>, Radiology<sup>29</sup>, University Medical Center Groningen;

Department of Neurology<sup>30</sup>, Radiology<sup>31</sup>, Atrium Medical Center, Heerlen;

Department of Neurology<sup>32</sup>, Radiology<sup>33</sup>, Catharina Hospital, Eindhoven;

Department of Neurology<sup>34</sup>, Radiology<sup>35</sup>, Medisch Spectrum Twente, Enschede;

Department of Radiology<sup>36</sup>, Amsterdam UMC, Vrije Universiteit van Amsterdam, Amsterdam;

Department of Radiology<sup>37</sup>, Noordwest Ziekenhuisgroep, Alkmaar;

Department of Radiology<sup>38</sup>, Texas Stroke Institute, Texas, United States of America.